Loading company
Ascendis Pharma A/S
ASND · Nasdaq · ·
Next earnings: November 11, 2026
$228.11-0.8%Sep 29 close
- 1M
- -8.0%
- 6M
- +4.5%
- 1Y
- +14.7%
- 5Y
- +39.6%
ASND · Nasdaq · ·
Next earnings: November 11, 2026
$228.11-0.8%Sep 29 close
Ascendis Pharma A/S is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $385.3M | $179.5M | +114.68% |
| Profit | -$38.1M | -$43.7M | +12.76% |
| Profit per share | $3.21 | -$1.79 | +279.11% |
| Free Cash Flow | -$64.3M | -$142.7M | +54.97% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
The quote and the company description come from the 6-K Ascendis Pharma A/S filed on August 13, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Ascendis Pharma A/S has no earnings call transcript available.